<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603977</url>
  </required_header>
  <id_info>
    <org_study_id>GZ8H-2017014</org_study_id>
    <nct_id>NCT03603977</nct_id>
  </id_info>
  <brief_title>Simplified Treatment of Anti-retrovirus in China (C-STAR)</brief_title>
  <official_title>A Simplified Therapy Regimen Study of Lopinavir and Ritonavir Combined With Lamivudine for HIV-1 Infected Patients in the Real World of China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou 8th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guiyang Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Kunming</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second People's Hospital of Nanjing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Guilin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Longtan hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fourth People’s Hospital of Nanning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LiuZhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The sixth people's hospital of Shenyang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Sixth People's Hospital of Henan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Sixth People's Hospital of Xinjiang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Eighth People's Hospital of Xi'an</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou 8th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1
      infected patients in Chinese real word.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an phase IV open-label, multicenter, single-arm clinical trial in. A total of 600
      cases were planned to be recruited. These cases were given simplified therapy regimen of
      lopinavir (200mg) and ritonavir (50mg) (500mg, oral, bid ) combined with lamivudine (300mg,
      oral, qd. The observation duration is thirty-sixth months. Patients will be followed up
      before and 12, 24 and 36 months after receiving the simplified regimen, observing the viral
      inhibition rate and the change of CD4 cell count, the safety and patients'compliance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of virus inhibition</measure>
    <time_frame>36 Months</time_frame>
    <description>the ratio of HIV RNA&lt; 50 copies/mL at 12, 24 or 36 months after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The immunological ability</measure>
    <time_frame>36 Months</time_frame>
    <description>the count of CD4 cells</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The level of compliance</measure>
    <time_frame>36 Months</time_frame>
    <description>To explicit the number of people who have completed the treatment</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Lpv/r+3TC</arm_group_label>
    <description>These cases were given simplified therapy regimen including lopinavir(200mg) and ritonavir(50mg)500 mg,oral,bid) combined with lamivudine (300 mg,oral,qd).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lpv/r+3TC</intervention_name>
    <description>It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.</description>
    <arm_group_label>Lpv/r+3TC</arm_group_label>
    <other_name>A simplified therapy regimen</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are prescribed to take the simplified therapy regimen (LPV/r+ 3TC) because
        they are unable to tolerate the side-effect of or are not fit for the first-line free
        regimen in China, for example renal failure or osteoporosis, according to clinical
        judgment, no matter of the HIV-RNA viral loads and CD4 cell counts.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infection confirmed

          2. Agree to use simplified therapy regimen.

          3. Agree to detect CD4 count at least once per half a year

        Exclusion Criteria:

          1. Have participated in HIV vaccine clinical trial or other drug trials in the past three
             months.

          2. Patients who could not complete the scheduled follow-up (such as weakness and poor
             compliance).

          3. Patients who have the history of resistance or allergy to LPV/r or 3TC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiping Cai, Bachelor</last_name>
    <role>Study Chair</role>
    <affiliation>Guangzhou 8th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linghua Li, Doctor</last_name>
    <phone>020-83710825</phone>
    <email>llheliza@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weiping Cai, Bachelor</last_name>
    <phone>020-83710816</phone>
    <email>gz8hcwp@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou 8th People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linghua Li, Doctor</last_name>
      <phone>020-83710825</phone>
      <email>llheliza@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Weiping Cai, Bachelor</last_name>
      <phone>020-83710816</phone>
      <email>gz8hcwp@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ; GARDEL Study Group. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014 Jul;14(7):572-80. doi: 10.1016/S1473-3099(14)70736-4. Epub 2014 Apr 27.</citation>
    <PMID>24783988</PMID>
  </reference>
  <reference>
    <citation>Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM; OLE/RIS-EST13 Study Group. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015 Jul;15(7):785-92. doi: 10.1016/S1473-3099(15)00096-1. Epub 2015 Jun 7. Erratum in: Lancet Infect Dis. 2015 Aug;15(8):875.</citation>
    <PMID>26062880</PMID>
  </reference>
  <reference>
    <citation>Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E; MOBIDIP study group. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Lancet HIV. 2017 Sep;4(9):e384-e392. doi: 10.1016/S2352-3018(17)30069-3. Epub 2017 May 28.</citation>
    <PMID>28566227</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou 8th People's Hospital</investigator_affiliation>
    <investigator_full_name>Linghua LI</investigator_full_name>
    <investigator_title>Vice Chief physician</investigator_title>
  </responsible_party>
  <keyword>Simplified Therapy Regimen</keyword>
  <keyword>Real World Study</keyword>
  <keyword>HIV-1-infected patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

